 Postmenopausal, ER andor PgR positive breast cancer patients eligible for adjuvant hormonal treatment HT, who are admitted for treatment and follow-up at the participating sites, will be enrolled in the trial. Study subjects will be treated with standard adjuvant hormonal therapy for a total of 5 years or until disease relapse or until HT is permanently discontinued for other reasons. 